Keyphrases
Children's Oncology Group
91%
Acute Myeloid Leukemia
77%
Pediatric Leukemia
55%
Myelodysplastic Syndrome
35%
Childrens
29%
Oncology
29%
Gemtuzumab Ozogamicin
28%
Childhood Acute Lymphoblastic Leukemia
20%
Fluorescence in Situ Hybridization
20%
Event-free Survival
19%
Overall Survival
17%
Relapse Risk
16%
Fanconi Anemia
16%
Pediatric Patients
15%
CD33
15%
Chronic Myeloid Leukemia
14%
Poor Outcome
13%
Leukemia
13%
Confidence Interval
13%
Hematopoietic Cell Transplantation
13%
Myeloid Leukemia
12%
Improved Outcomes
12%
Chemotherapy
12%
Pediatric
12%
Leukemia Patients
12%
Acute Lymphoblastic Leukemia
12%
Clinical Outcomes
11%
FLT3-ITD
11%
De Novo Acute Myeloid Leukemia
11%
Complete Remission
11%
Minimal Residual Disease
11%
Prognostic Implications
10%
Group Studies
10%
Population-based Study
10%
SNP
9%
High-level Expression
9%
Microdeletion
9%
Odds Ratio
9%
Standard Risk
8%
Acute Promyelocytic Leukemia
8%
American College of Medical Genetics
8%
Copy number Variation
8%
Group Communication Protocol
8%
Disease Pattern
8%
Adult Acute Lymphoblastic Leukemia
8%
Cytarabine
8%
High Dose
8%
Disease-free Survival
7%
High Risk
7%
Duplication
7%
Medicine and Dentistry
Oncology
100%
Acute Myeloid Leukemia
90%
Pediatric Acute Myeloid Leukemia
48%
Myelodysplastic Syndrome
35%
Disease
33%
Overall Survival
28%
Event Free Survival
24%
Pediatrics
19%
Minimal Residual Disease
17%
Prevalence
14%
Myeloid Leukemia
14%
Fanconi Anemia
13%
Pediatrics Patient
13%
Fluorescence in Situ Hybridization
11%
Cytarabine
11%
Leukemia
10%
Flow Cytometry
9%
Odds Ratio
9%
Disease Free Survival
9%
Chronic Myelogenous Leukemia
9%
Acute Lymphoblastic Leukemia
9%
Hematopoietic Stem Cell Transplantation
8%
Group Trial
8%
Adult Myeloid Leukemia
8%
Drug Megadose
8%
Hazard Ratio
8%
Diagnosis
8%
De Novo Acute Myeloid Leukemia
8%
Cell Transplantation
8%
Hematopoietic Stem Cell
8%
Exon
7%
Transplantation
7%
Congenital Malformation
7%
Morphology
7%
Down Syndrome
7%
Core Binding Factor
6%
Retrospective Study
6%
Metaphase
6%
Karyotype
6%
Gemtuzumab Ozogamicin
6%
Anthracycline
5%
Acute Promyelocytic Leukemia
5%
Acute Leukemia
5%
Single Nucleotide Polymorphism
5%
Risk Stratification
5%
Adverse Outcome
5%
Aneuploidy
5%
Blood Disorder
5%
Drug Dose Reduction
5%
Allograft
5%
Biochemistry, Genetics and Molecular Biology
Myeloid
69%
Cytogenetics
39%
Fluorescence in Situ Hybridization
25%
Genetics
14%
Mouse
12%
Stem Cell
11%
Prevalence
11%
Event Free Survival
10%
Overall Survival
9%
Mosaicism
9%
Metaphase
9%
Gemtuzumab Ozogamicin
8%
Medical Genetics
8%
G Banding
8%
DM Domain
8%
Single Nucleotide Polymorphism
8%
CD33
8%
Single-Nucleotide Polymorphism
8%
Cytarabine
7%
Genotyping
7%
Comparative Genomic Hybridization
7%
Exon
6%
Chromosomal Abnormalities
6%
Karyotype
6%
NUP98
6%
Retrospective Study
6%
Core Binding Factor
6%
WT1
5%
Loss of Heterozygosity
5%
Aneuploidy
5%
Medical Genomics
5%
Cell Transplantation
5%
Gene Mutation
5%
Transposable Element
5%
Microarrays
5%
